USA flag logo/image

An Official Website of the United States Government

A novel therapeutic antibody for treatment of ischemic stroke.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89402
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
NS061374
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANTGEN, INC.
AVANTGEN, INC. 10151 Pacific Mesa Blvd. SAN DIEGO, CA 92129-4571
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: A novel therapeutic antibody for treatment of ischemic stroke.
Agency: HHS
Contract: 1R43NS061374-01A1
Award Amount: $220,061.00
 

Abstract:

DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. Despite its prevalence, current treatment options are limited and surviving stroke is still associated with serious morbidity issues. The most recent ther apy for ischemic stroke, Alteplase, was approved by the FDA over a decade ago and has serious limitations due to the potential for inducing bleeding complications if administered more than 3 hours after the acute event, and its use is counter-indicated for hemorrhagic strokes. Even so, clinical studies suggest that the combination of this drug with subsequent anti-thrombotic treatment such as aspirin, improves patient outcome. However, such agents can not be used concurrently with tPA because of their poten tial to exacerbate bleeding despite the known role platelets play in the downstream events triggered by the initial ischemic event. The approach described in this application is to develop a therapeutic antibody directed against a novel target for stroke. Not only does the -platelet GPIba interaction provide a promising target to develop anti-thrombotics with a reduced potential for bleeding complications, but this interaction also appears to play a major role in the secondary thrombosis associated with inf lammatory endothelial responses during reperfusion injury. A successful outcome of the research described in this Phase I project, coupled with the research planned for Phase II, would allow us to develop proof of concept and completion of toxicology studi es for a promising new therapeutic agent for the treatment of ischemic stroke. PUBLIC HEALTH RELAVANCE: Stroke is the third leading cause of death in the United States. Despite its prevalence, current treatment options are limited and surviving stroke is s till associated with serious morbidity issues. The most recently approved therapy (drug) for ischemic stroke, Acteplase, was approved by the FDA over a decade ago and has serious limitations because of its potential for inducing bleeding complications if a dministered more than 3 hours after the stroke has occurred, which greatly limits its use. If successful, the research we are proposing could lead to a new drug to more effectively treat ischemic stroke.

Principal Investigator:

Business Contact:


cmwoods@avantgen.com
Small Business Information at Submission:

AVANTGEN, INC.
AVANTGEN, INC. 12240 KATYDID CIR SAN DIEGO, CA 92129

EIN/Tax ID: 120215784
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No